Healius Ltd's stock price plummeted 10.31% during intraday trading on Wednesday, marking a significant decline for the healthcare company.
The sharp drop follows the company's announcement of inadequate funding which has forced difficult decisions including staff reductions. Concurrently, Healius has engaged UBS to explore the sale of its Agilex Biolabs unit and is conducting a broader strategic review of its assets.
The company also provided its financial expectations for FY 2026, forecasting group underlying EBITDA between A$259 million and A$264 million, and underlying EBIT in the range of A$30 million to A$35 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.